Clinical Trials Logo

Secondary Myelofibrosis clinical trials

View clinical trials related to Secondary Myelofibrosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02528877 Withdrawn - Clinical trials for Secondary Acute Myeloid Leukemia

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with tacrolimus and sirolimus in preventing acute graft-versus-host disease during reduced intensity donor hematopoietic cell transplant in patients with myelofibrosis. Sometimes transplanted cells from a donor can attack the normal tissue of the transplant patient called graft-versus-host disease. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also reduce graft-versus-host disease by reducing inflammation and immune modulation. Giving ruxolitinib phosphate together with tacrolimus and sirolimus after transplant may prevent graft-versus-host disease.

NCT ID: NCT00722254 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Start date: June 2006
Phase: N/A
Study type: Observational

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.